Dornase alfa

Identification

Name
Dornase alfa
Accession Number
DB00003 / 953A26OA1Y
Groups
Pulmozyme
Description

Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. it's far produced in genetically changed chinese language hamster ovary (CHO) cells the usage of recombinant DNA era. The 260-amino acid series of dornase alfa is same to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to five´-phosphodinucleotide and five´-phosphooligonucleotide cease products with out affecting intracellular DNA. In people with cystic fibrosis, extracellular DNA, that is a very viscous anion, is launched by degenerating leukocytes that acquire for the duration of inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.

Pharmacology

Pharmacodynamics

Cystic fibrosis (CF) is a disease characterized by the retention of viscous purulent secretions in the airways. These thick secretions contribute both to reduced pulmonary function and to frequent pulmonary infection. Purulent pulmonary secretions of individuals with cystic fibrosis contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to these infections. Dornase alfa hydrolyzes the DNA in sputum of CF patients and reduces sputum viscosity and viscoelasticity. The enzyme does not appear to affect sputum in the absence of an inflammatory response to infection, nor does it affect the sputum of healthy individuals.

Indication

Used as adjunct therapy in the treatment of cystic fibrosis.

Action

Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.